Røysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, Di Tano G, Misuraca G, Maggioni A P, Tognoni G, Tavazzi L, Latini R, GISSI-HF Investigators |
Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial
Am Heart J 2010. 160 : 286 - 293 |
Røsjø H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere T, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland T, GISSI-HF Investigators |
Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial
Eur J Heart Fail 2010. 12 : 519 - 556 |
Røsjø H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland T; GISSI-HF Investigators. |
Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial.
Eur J Heart Fail 2010. 12(6) : 549 - 556 |
GISSI-HF Investigators |
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
Lancet 2008. DOI:10.1016/S0140-6736(08)61239-8 |
GISSI-HF Investigators |
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
Lancet 2008. DOI:10.1016/S0140-6736(08)61240-4 |
Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL and Porcu M, on behalf of GISSI-HF Investigators |
Rationale and Design of the GISSI Heart Failure Trial: a Large Trial to Assess the Effects of n-3 Polyunsaturated Fatty Acids and Rosuvastatin in Symptomatic Congestive Heart Failure
Eur J Heart Fail 2004. 6 : 635 - 641 |
